Physician profile
David Wang
NPI 1376002642
$2,383.95
in general payments reported to CMS, 2019-2025
25 companies · $2,017 in 2025
The $2,017 reported for 2025 was more than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $96.27 · 2024: $271 · 2025: $2,017.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,185 · Education: $199.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,184.96 |
| Education | $198.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $665.49 | 2024-2025 | Otezla, Uplizna, Evenity |
| Janssen Biotech, INC. | $243.08 | 2025 | Tremfya |
| Abbvie INC. | $175.49 | 2024-2025 | |
| Ani Pharmaceuticals, INC. | $151.53 | 2025 | Purified Cortrophin Gel |
| Aurinia Pharma U.S., INC. | $125.18 | 2023-2025 | Lupkynis |
| Sanofi-Aventis U.S. LLC | $120.66 | 2025 | |
| Novartis Pharmaceuticals Corporation | $102.59 | 2025 | |
| Ucb, INC. | $96.71 | 2025 | Bimzelx |
| Astrazeneca Pharmaceuticals LP | $88.49 | 2025 | Saphnelo, Breztri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $81.56 | 2025 | Ofev |
| Pfizer INC. | $58.96 | 2025 | |
| Invivyd INC | $58.83 | 2025 | Pemgarda |
| Alexion Pharmaceuticals, INC. | $51.79 | 2024-2025 | Strensiq |
| Grifols USA, LLC | $48.72 | 2024 | Xembify, Prolastin-C Liquid |
| Novo Nordisk INC | $48.20 | 2024-2025 | Wegovy |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Beta Bionics, INC. | $44.65 | 2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Inset, Ilet Insulin Infusion Kit Contact Detach |
| Organon LLC | $40.59 | 2025 | Hadlima, Renflexis |
| Mannkind Corporation | $32.99 | 2025 | |
| Genzyme Corporation | $25.09 | 2025 | |
| Madrigal Pharmaceuticals | $24.91 | 2025 | Rezdiffra |
| Esperion Therapeutics, INC. | $24.11 | 2025 | Nexletol |
| Kyowa Kirin, INC. | $21.88 | 2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $19.17 | 2025 | Glassia |
| E.R. Squibb & Sons, L.L.C. | $19.16 | 2025 | Orencia |
| Lilly USA, LLC | $14.12 | 2025 | Mounjaro, Zepbound |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Wang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.